Medtronic ($MDT) said in a regulatory filing that three shareholder lawsuits against current and former executives were voluntarily dismissed. The lawsuits had to with improper marketing of the Infuse bone graft for off-label purposes not approved by the FDA. The device has long been a source of controversy. In 2012, Medtronic agreed to pay $85 million to settle a shareholder class action lawsuit brought forth by the Minneapolis Firefighters' Relief Association, alleging that the company failed to reveal a large proportion of the bone graft's sales came from off-label uses. More (sub. req.)